Benefits risks anemia correction recombinant human erythropoietin children hemodialysis children renal failure age range years months years months median years months long-term hemodialysis successful correction anemia intravenous administration recombinant human erythropoietin dosage weeks IU/kg/wk Mean hemoglobin concentration gm/dl Blood cell counts correction anemia dialysis important children compliant water restriction hemoglobin concentration improvement quality life tolerance physical effort exercise tolerance ventilatory anaerobic threshold correction subclinical central nervous system abnormalities evoked potentials reduction bleeding time Few side effects severe hypertension patient postdialysis hematocrit episodes hypertransaminasemia evidence liver dysfunction children renal failure use recombinant human erythropoietin anemia safe advisable resolution many symptoms anemia 